Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b/3 Multicenter, Randomized, Double-Masked, Dose-Ranging Study Comparing the Efficacy and Safety of Emixustat Hydrochloride (ACU-4429) With Placebo for the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration

Next Previous
X
Search
Trial Profile

A Phase 2b/3 Multicenter, Randomized, Double-Masked, Dose-Ranging Study Comparing the Efficacy and Safety of Emixustat Hydrochloride (ACU-4429) With Placebo for the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 01 Jul 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emixustat (Primary)
  • Indications Dry age-related macular degeneration; Dry macular degeneration
  • Focus Registrational; Therapeutic Use
  • Acronyms SEATTLE
  • Sponsors Acucela; Kubota Vision

    • Most Recent Events

    • 20 Feb 2020 According to an Acucela media release, the company has changed its name to Kubota Vision, effective from 1 Apr 2020.
    • 01 Oct 2018 According to results published in an Ophthalmology Journal, the number of subjects randomized to the 10 mg emixustat arm was less than the other arms because of a temporary suspension of enrollment in this arm due to concerns by the Data Monitoring Committee over decreases in LL-BCVA in some subjects.This issue was further investigated and on the basis of additional data, enrollment was resumed into this arm.
    • 13 Jun 2016 According to an Acucela Inc. media release, the company will discontinue further analysis of the clinical data from this study pertaining to geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top